Transgenic animal models in toxicology: historical perspectives and future outlook.
暂无分享,去创建一个
Mirjam Luijten | Darrell R Boverhof | B Bhaskar Gollapudi | Jan van Benthem | Mugimane G Manjanatha | David Jacobson-Kram | M. Chamberlain | M. Manjanatha | F. Gonzalez | A. Maggi | C. Elcombe | M. Luijten | A. Jacobs | L. G. Hernández | D. Boverhof | Frank J Gonzalez | Adriana Maggi | Mark P Chamberlain | Clifford R Elcombe | Robert H Heflich | Lya G Hernández | Abigail C Jacobs | J. Benthem | B. Gollapudi | R. Heflich | D. Jacobson-Kram | Lya G. Hernández
[1] J. Short,et al. Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacl shuttle vector , 1991, Environmental and molecular mutagenesis.
[2] A. Moschetta,et al. Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. , 2009, Frontiers in bioscience.
[3] K A McAllister,et al. Mammary Tumor Induction and Premature Ovarian Failure in ApcMin Mice Are Not Enhanced by Brca2 Defi ciency , 2001, Toxicologic pathology.
[4] K. Morimura,et al. Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.
[5] C. Bradfield,et al. The Aryl Hydrocarbon Receptor sans Xenobiotics: Endogenous Function in Genetic Model Systems , 2007, Molecular Pharmacology.
[6] F. Gonzalez,et al. Pregnane X receptor‐ and CYP3A4‐humanized mouse models and their applications , 2011, British journal of pharmacology.
[7] Timothy M Willson,et al. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. , 2002, Endocrine reviews.
[8] J. Vijg,et al. Transgenic mouse models for studying mutations in vivo: applications in aging research , 1997, Mechanisms of Ageing and Development.
[9] C. Elcombe,et al. The coordinate regulation of DNA synthesis and suppression of apoptosis is differentially regulated by the liver growth agents, phenobarbital and methylclofenapate. , 1998, Carcinogenesis.
[10] A. Jaiswal,et al. Disruption of the DT Diaphorase (NQO1) Gene in Mice Leads to Increased Menadione Toxicity* , 1998, The Journal of Biological Chemistry.
[11] Thomas Hartung,et al. Are in vitro tests suitable for regulatory use? , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[12] U. Pitkänen,et al. Liver size and indices of drug metabolism in alcoholics , 1978, European Journal of Clinical Pharmacology.
[13] T. Pineau,et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor , 1995, Science.
[14] L. Moore,et al. Functional and structural comparison of PXR and CAR. , 2003, Biochimica et biophysica acta.
[16] R. Tennant,et al. Follicular origin of epidermal papillomas in v-Ha-ras transgenic TG.AC mouse skin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[17] E. Candido,et al. Transgenic Caenorhabditis elegans strains as biosensors. , 1996, Trends in biotechnology.
[18] Philippe Soriano. Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.
[19] D. Zalko,et al. A CASCADE of effects of bisphenol A. , 2009, Reproductive toxicology.
[20] Markus Reischl,et al. Zebrafish embryos as models for embryotoxic and teratological effects of chemicals. , 2009, Reproductive toxicology.
[21] R. Roberts,et al. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. , 1996, Carcinogenesis.
[22] F. Gonzalez,et al. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. , 2005, Endocrinology.
[23] F. Bunz,et al. ATM and ATR: Components of an Integrated Circuit , 2007, Cell cycle.
[24] J. Gustafsson,et al. Aryl hydrocarbon receptor-mediated signal transduction. , 1997, Critical reviews in toxicology.
[25] D. Nebert,et al. Toward the evaluation of function in genetic variability: Characterizing human SNP frequencies and establishing BAC‐transgenic mice carrying the human CYP1A1_CYP1A2 locus , 2005, Human mutation.
[26] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[27] Takahiro Ochiya,et al. Generation of genetically modified rats from embryonic stem cells , 2010, Proceedings of the National Academy of Sciences.
[28] R. Tennant,et al. Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment , 2000 .
[29] A. Walker,et al. The toxicology of dieldrin (HEOD). II. Comparative long-term oral toxicity studies in mice with dieldrin, DDT, phenobarbitone, -BHC and -BHC. , 1973, Food and cosmetics toxicology.
[30] R. de Kanter,et al. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.
[31] D. Nebert,et al. Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate , 2006, Molecular Pharmacology.
[32] C. Wolf,et al. Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[33] G. Perdew,et al. Ligand Selectivity and Gene Regulation by the Human Aryl Hydrocarbon Receptor in Transgenic Mice , 2009, Molecular Pharmacology.
[34] A. Børresen. Oncogenesis in ovarian cancer , 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.
[35] D E Robinson,et al. Background and Framework for ILSI's Collaborative Evaluation Program on Alternative Models for Carcinogenicity Assessment , 2001, Toxicologic pathology.
[36] M. P. Carty,et al. DNA polymerase eta, a key protein in translesion synthesis in human cells. , 2010, Sub-cellular biochemistry.
[37] J M Ward,et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. , 1998, Toxicology and applied pharmacology.
[38] T. Pineau,et al. Role of CYP 2 E 1 in the Hepatotoxicity of Acetaminophen * , 1996 .
[39] B. Allen,et al. Analysis of in vivo mutation data can inform cancer risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.
[40] T. Nohmi,et al. Heavy‐ion‐induced mutations in the gpt delta transgenic mouse: Effect of p53 gene knockout , 2002, Environmental and molecular mutagenesis.
[41] T. Nohmi,et al. Novel transgenic rat for in vivo genotoxicity assays using 6‐thioguanine and Spi− selection , 2003, Environmental and molecular mutagenesis.
[42] M. Waterman,et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] A. Maggi,et al. In vivo imaging of transcriptionally active estrogen receptors , 2003, Nature Medicine.
[44] G. Riou. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. , 1988, Cancer surveys.
[45] H. Aburatani,et al. Mmh/Ogg1 gene inactivation results in accumulation of 8-hydroxyguanine in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] F. Gonzalez,et al. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.
[47] U. Pitkänen,et al. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants , 2004, European Journal of Clinical Pharmacology.
[48] J. Idle,et al. A Double Transgenic Mouse Model Expressing Human Pregnane X Receptor and Cytochrome P450 3A4 , 2008, Drug Metabolism and Disposition.
[49] Ai-Ming Yu,et al. THE CYP2E1-HUMANIZED TRANSGENIC MOUSE: ROLE OF CYP2E1 IN ACETAMINOPHEN HEPATOTOXICITY , 2005, Drug Metabolism and Disposition.
[50] J. Vijg,et al. Bacteriophage Lambda and Plasmid lacZ Transgenic Mice for Studying Mutations in Vivo , 1996 .
[51] L. Donehower,et al. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. , 2000, Cancer research.
[52] G. Perdew,et al. Regulation of Gene Expression , 2008, Goodman's Medical Cell Biology.
[53] J. French,et al. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[54] D. Nebert,et al. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.
[55] J. Foster. Cell Death and Cell Proliferation in the Control of Normal and Neoplastic Tissue Growth , 2000, Toxicologic pathology.
[56] A. Maggi,et al. Molecular imaging, an innovative methodology for whole-body profiling of endocrine disrupter action. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[57] R. Roberts,et al. The perturbation of apoptosis and mitosis by drugs and xenobiotics. , 1999, Pharmacology & therapeutics.
[58] B. Neuschwander‐Tetri,et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR , 2000, Nature.
[59] Robert Kavlock,et al. The U.S. Environmental Protection Agency Strategic Plan for Evaluating the Toxicity of Chemicals , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[60] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[61] M. Ingelman-Sundberg,et al. Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression , 2008, Drug Metabolism and Disposition.
[62] G. Perdew,et al. Differential gene regulation by the human and mouse aryl hydrocarbon receptor. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[63] E Spencer Williams,et al. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH. , 2009, Regulatory toxicology and pharmacology : RTP.
[64] K. Kinzler,et al. The multistep nature of cancer. , 1993, Trends in genetics : TIG.
[65] Alan R. Boobis,et al. IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans , 2008, Critical reviews in toxicology.
[66] A. Poso,et al. Amino Acids Important for Ligand Specificity of the Human Constitutive Androstane Receptor* , 2005, Journal of Biological Chemistry.
[67] H. Greim,et al. CYP1B1 determines susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. , 2003, Carcinogenesis.
[68] C. Wolf,et al. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. , 2008, The Journal of clinical investigation.
[69] M. Cimino,et al. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide , 2008, Environmental and molecular mutagenesis.
[70] Vicki L Dellarco,et al. Mode of action in relevance of rodent liver tumors to human cancer risk. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[71] A. Bauer,et al. Use of genetically modified mouse models to assess pathways of benzene-induced bone marrow cytotoxicity and genotoxicity. , 2005, Chemico-biological interactions.
[72] A. Look,et al. Cell transformation by ras and regulation of its protein product. , 1993, Ciba Foundation symposium.
[73] R. Caprioli,et al. The Anti-tumorigenic Properties of Peroxisomal Proliferator-activated Receptor α Are Arachidonic Acid Epoxygenase-mediated* , 2010, The Journal of Biological Chemistry.
[74] J. Idle,et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.
[75] J Vijg,et al. Plasmid rescue from transgenic mouse DNA using LacI repressor protein conjugated to magnetic beads. , 1993, BioTechniques.
[76] P. Apostoli,et al. Isomer-specific activity of dichlorodyphenyltrichloroethane with estrogen receptor in adult and suckling estrogen reporter mice. , 2002, Endocrinology.
[77] R. Mittelstaedt,et al. Induction of 6‐thioguanine‐resistant lymphocytes in fischer 344 rats following in vivo exposure to n‐ethyl‐n‐nitrosourea and cyclophosphamide , 1991, Environmental and molecular mutagenesis.
[78] James E Klaunig,et al. The Human Relevance of Information on Carcinogenic Modes of Action: Overview , 2003, Critical reviews in toxicology.
[79] Ignacio Anegon,et al. Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases , 2009, Science.
[80] F. Gonzalez,et al. Targeted Disruption of the Microsomal Epoxide Hydrolase Gene , 1999, The Journal of Biological Chemistry.
[81] T. Jacks,et al. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. , 2005, Cancer research.
[82] H. van Steeg,et al. Transgenic and knockout mice for DNA repair functions in carcinogenesis and mutagenesis. , 2003, Toxicology.
[83] C. Tohyama,et al. Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[84] J. Idle,et al. Rifampicin-Activated Human Pregnane X Receptor and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity , 2009, Drug Metabolism and Disposition.
[85] R. Tukey,et al. Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus* , 2005, Journal of Biological Chemistry.
[86] P. Slijepcevic. The role of DNA damage response proteins at telomeres--an "integrative" model. , 2006, DNA repair.
[87] Riou Gf. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. , 1988 .
[88] M. Veldhoen,et al. The aryl hydrocarbon receptor: fine-tuning the immune-response. , 2010, Current opinion in immunology.
[89] T. Willson,et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[90] Ai-Ming Yu,et al. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models , 2011, Drug metabolism reviews.
[91] D. Hanahan,et al. Transgenic mice as probes into complex systems. , 1989, Science.
[92] C. Esser,et al. The aryl hydrocarbon receptor (AHR), a novel regulator of human melanogenesis , 2010, Pigment cell & melanoma research.
[93] N. Gorelick,et al. Prospects for safety testing: A strategy for the application of transgenic rodent mutagenesis assays , 1996, Environmental and molecular mutagenesis.
[94] Hiroshi Suzuki,et al. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent , 2005, Oncogene.
[95] J. Vijg,et al. Spontaneous and X-ray-induced deletion mutations in a LacZ plasmid-based transgenic mouse model. , 1995, Mutation research.
[96] G. Douglas,et al. Cytogenetic mapping of λgt10 lacZ sequences in the transgenic mouse strain 40.6 (MutaTMMouse) , 1995 .
[97] F. Gonzalez. The 2006 Bernard B . Brodie Award Lecture CYP 2 E 1 , 2006 .
[98] R. Edwards,et al. Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.
[99] E. Seeberg,et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[100] J. Olsen,et al. Cancer among epileptic patients exposed to anticonvulsant drugs. , 1989, Journal of the National Cancer Institute.
[101] F. Gonzalez,et al. Targeted Disruption of Soluble Epoxide Hydrolase Reveals a Role in Blood Pressure Regulation* , 2000, The Journal of Biological Chemistry.
[102] Mario R. Capecchi,et al. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century , 2005, Nature Reviews Genetics.
[103] J. Olsen,et al. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. , 1995, Cancer research.
[104] J. Ward,et al. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. , 2006, Carcinogenesis.
[105] J. Corton,et al. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. , 1996, Toxicology and applied pharmacology.
[106] J. Heideman. Transgenic rats: a discussion. , 1991, Biotechnology.
[107] G. Perdew,et al. Transgenic Humanized AHR Mouse Reveals Differences between Human and Mouse AHR Ligand Selectivity. , 2009, Molecular and cellular pharmacology.
[108] J. Idle,et al. The Pregnane X Receptor Gene-Humanized Mouse: A Model for Investigating Drug-Drug Interactions Mediated by Cytochromes P450 3A , 2007, Drug Metabolism and Disposition.
[109] T. Pineau,et al. Role of CYP2E1 in the Hepatotoxicity of Acetaminophen (*) , 1996, The Journal of Biological Chemistry.
[110] Lung-Ji Chang,et al. Efficient generation of transgenic rats through the male germline using lentiviral transduction and transplantation of spermatogonial stem cells. , 2006, Journal of andrology.
[111] F. Gonzalez,et al. Transgenic models in xenobiotic metabolism and toxicology. , 2002, Toxicology.
[112] G. Douglas,et al. Treatment and sampling protocols for transgenic mutation assays , 2003, Environmental and molecular mutagenesis.
[113] F. Gonzalez. CYP2E1 , 2006, Drug Metabolism and Disposition.
[114] B. Stockinger. Beyond toxicity: aryl hydrocarbon receptor-mediated functions in the immune system , 2009, Journal of biology.
[115] G. Williams,et al. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.
[116] J. Short,et al. The use of shuttle vectors for mutation analysis in transgenic mice and rats. , 1994, Mutation research.
[117] S. Hussain,et al. p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Human Risk Assessment , 2000, Annals of the New York Academy of Sciences.
[118] D C Wight,et al. Transgenic mice: a decade of progress in technology and research. , 1994, Mutation research.
[119] D. Smith,et al. Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. , 1993, Pharmacogenetics.
[120] Y Fujii-Kuriyama,et al. Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. , 1994, The Journal of biological chemistry.
[121] N. Henderson,et al. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[122] Jae Young Lee,et al. Structure and Mechanism of Human DNA Polymerase η , 2010, Nature.
[123] D. Nebert,et al. Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line. , 2007, Biochemical and biophysical research communications.
[124] M Younes,et al. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.
[125] R. Palmiter,et al. Metallothionein-human GH fusion genes stimulate growth of mice. , 1983, Science.
[126] J. Sedivy,et al. Analysis of biological selections for high-efficiency gene targeting , 1995, Molecular and cellular biology.
[127] D. Moore,et al. Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR , 2002, Science.
[128] L. Moore,et al. Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.
[129] Carolyn Vickers,et al. IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .
[130] F. Gonzalez,et al. The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARα , 2008 .
[131] Jiunn H. Lin,et al. CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications , 2006, Pharmaceutical Research.
[132] J. Vijg,et al. Background mutations and polymorphisms in lacZ‐plasmid transgenic mice , 1999, Environmental and molecular mutagenesis.
[133] J. Ward,et al. Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α , 2004, Cancer Research.
[134] E. Sandgren,et al. Cell‐specific transgene expression from a widely transcribed promoter using Cre/lox in mice , 2002, Genesis.
[135] C. Harris,et al. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. , 2000, Mutation research.
[136] H. Lynch,et al. Cancer risk in mismatch repair gene mutation carriers , 2004, Familial Cancer.
[137] M. Lavin,et al. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer , 2008, Nature Reviews Molecular Cell Biology.
[138] M. Katsuki,et al. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. , 1990, Oncogene.
[139] Yanjue Wu,et al. Transgenic C. elegans as a model in Alzheimer's research. , 2005, Current Alzheimer research.
[140] X. Cui,et al. Targeted integration in rat and mouse embryos with zinc-finger nucleases , 2011, Nature Biotechnology.
[141] R. Jaenisch. Transgenic animals. , 1988, Science.
[142] K. Korach,et al. Increased blood pressure in mice lacking cytochrome P450 2J5 , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[143] J. Peters,et al. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.
[144] P. Leder,et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.
[145] P. Apostoli,et al. Whole body action of xenoestrogens with different chemical structures in estrogen reporter male mice. , 2004, Toxicology.
[146] J. Ward,et al. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[147] H. Frucht,et al. The Genetics of Colorectal Cancer , 2002, Annals of Internal Medicine.
[148] R. Schulte‐Hermann,et al. Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. , 1991, Cancer research.
[149] D. Nebert,et al. Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. , 2005, Chemical research in toxicology.
[150] M. Capecchi,et al. Altering the genome by homologous recombination. , 1989, Science.
[151] R. Maronpot,et al. The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice , 2004, Cancer Research.
[152] R. Tennant,et al. Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[153] G. Lucignani,et al. Techniques: reporter mice - a new way to look at drug action. , 2004, Trends in pharmacological sciences.
[154] M. Waterman,et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. , 2006, The Journal of clinical investigation.
[155] R. Jaenisch,et al. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[156] R. Tennant,et al. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. , 1996, Mutation research.
[157] F. Gonzalez,et al. Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment , 2008, Journal of Pharmacology and Experimental Therapeutics.
[158] S. Teichberg,et al. The effects of phenobarbital and diphenylhydantoin on liver function and morphology. , 1980, The Journal of pediatrics.
[159] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[160] T. Shimada,et al. Activation of procarcinogens by human cytochrome P450 enzymes. , 1998, Mutation research.
[161] F. Gonzalez,et al. The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[162] I. Lambert,et al. Detailed review of transgenic rodent mutation assays. , 2005, Mutation research.
[163] C. Wolf,et al. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[164] Christopher A Bradfield,et al. The search for endogenous activators of the aryl hydrocarbon receptor. , 2008, Chemical research in toxicology.
[165] B. Lake,et al. Effect of chronic phenobarbitone administration on liver tumour formation in the C57BL/10J mouse. , 2009, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[166] R. Feil,et al. Inducible Cre mice. , 2009, Methods in molecular biology.
[167] I. M. Jones,et al. A method to quantify spontaneous and in vivo induced thioguanine-resistant mouse lymphocytes. , 1985, Mutation research.
[168] J. Lehmann,et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. , 2002, Molecular pharmacology.
[169] K. Kolaja,et al. Reversibility of promoter induced hepatic focal lesion growth in mice. , 1996, Carcinogenesis.
[170] X. Sun,et al. Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation. , 2001, Endocrinology.
[171] O. Ueda,et al. Mutagenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the new gpt delta transgenic mouse. , 1999, Cancer letters.
[172] J. Manson,et al. Transgenic models of the transmissible spongiform encephalopathies , 2001, Expert Reviews in Molecular Medicine.
[173] L. Tesson,et al. Transgenesis in rats: Technical aspects and models , 1996, Transgenic Research.
[174] L. Donehower,et al. Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing , 2001, Toxicologic pathology.
[175] J. Short,et al. Development of a short-term, in vivo mutagenesis assay: the effects of methylation on the recovery of a lambda phage shuttle vector from transgenic mice. , 1990, Nucleic acids research.
[176] H. van Steeg,et al. DNA Repair—Deficient Xpa and Xpa/p53+/- Knock-Out Mice: Nature of the Models , 2001, Toxicologic pathology.
[177] J. Beijnen,et al. Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam , 2009, Drug Metabolism and Disposition.
[178] J. Ward,et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[179] S. Cohen,et al. Alternative Models for Carcinogenicity Testing: Weight of Evidence Evaluations Across Models , 2001, Toxicologic pathology.
[180] R. Jaenisch. Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[181] T. Kodama,et al. Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation , 2010, Journal of Pharmacology and Experimental Therapeutics.
[182] B. Komm,et al. An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals. , 2010, Molecular endocrinology.
[183] D. Davidson,et al. The CF mouse: an important tool for studying cystic fibrosis , 2001, Expert Reviews in Molecular Medicine.
[184] R. Cardiff,et al. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[185] D. Nebert,et al. Theophylline pharmacokinetics: comparison of Cyp1a1(−/−) and Cyp1a2(−/−) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice , 2005, Pharmacogenetics and genomics.
[186] F. Gonzalez,et al. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[187] D. Lowy,et al. Function and regulation of ras. , 1993, Annual review of biochemistry.
[188] L. Liaw,et al. Targeted Genome Modification in Mice Using Zinc-Finger Nucleases , 2010, Genetics.
[189] A. Maggi,et al. Differential effect of pure isoflavones and soymilk on estrogen receptor activity in mice. , 2009, Toxicology and applied pharmacology.
[190] Takayoshi Suzuki,et al. In vivo transgenic mutation assays. , 2003, Mutation research.
[191] T. Pineau,et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.
[192] C. Wolf,et al. In Vivo Responses of the Human and Murine Pregnane X Receptor to Dexamethasone in Mice , 2010, Drug Metabolism and Disposition.
[193] D. Moore,et al. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism , 2000, Nature.
[194] Xiaochao Ma,et al. The pregnane X receptor: from bench to bedside. , 2008, Expert opinion on drug metabolism & toxicology.
[195] M. Dickins. Induction of cytochromes P450. , 2004, Current topics in medicinal chemistry.
[196] S. Dertinger,et al. The in vivo pig‐a gene mutation assay, a potential tool for regulatory safety assessment , 2010, Environmental and molecular mutagenesis.
[197] P. Peltomäki,et al. The genetics of HNPCC: application to diagnosis and screening. , 2006, Critical reviews in oncology/hematology.
[198] J. Lehmann,et al. An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.
[199] M. De Felici,et al. Genistein is an efficient estrogen in the whole-body throughout mouse development. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[200] I. Mangelsdorf,et al. TRANSGENIC ANIMAL MUTAGENICITY ASSAYS , 2006 .
[201] J. Bailar,et al. Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[202] D. Nebert,et al. Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. , 2000, Biochemical and biophysical research communications.
[203] Rudolf B. Beems,et al. Xpa and Xpa/p53+/- Knockout Mice: Overview of Available Data , 2001, Toxicologic pathology.
[204] D. Moore,et al. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. , 2005, Molecular endocrinology.
[205] G. Perdew,et al. Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. , 2004, Molecular pharmacology.
[206] C. Hsieh,et al. Germline Competent Embryonic Stem Cells Derived from Rat Blastocysts , 2008, Cell.
[207] O. Ueda,et al. Other transgenic mutation assays: A new transgenic mouse mutagenesis test system using Spi− and 6‐thioguanine selections , 1996, Environmental and molecular mutagenesis.
[208] D W Nebert,et al. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[209] R. Tennant,et al. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. , 2000, Toxicologic pathology.